February JC at MSF: Trial of M72/AS01e Vaccine
North London TB Journal Club
by northlondontb
4y ago
Despite significant progress in the global fight against TB, there are no major game changers on the horizon to take the world towards TB elimination. A safe and effective vaccine would definitely be one. Is the M72/AS01E vaccine candidate that missing component? The Gates Foundation certainly think so, as the Gates MRI has obtained the licence to develop it further from GSK. Join us to review the evidence behind this exciting dream. Please join us at MSF on 19th February, 2020, to discuss the NEJM paper findings on this Vaccine. Full details can be found on the Upcoming Events Page ..read more
Visit website
November: Is ACF effective for high-prevalence settings?: Outcomes from the Vietnam Cluster RCT 2014–8
North London TB Journal Club
by northlondontb
4y ago
 Join us at LSHTM on November 27th to discuss the following paper. Full details can be found on the ‘Upcoming Events’ page. Marks et al. performed a cluster-randomized, controlled trial in a province in Vietnam, to compared the effectiveness of ACF and PCF for reducing the prevalence of tuberculosis. Prevalence for persons 15 years of age or older reduced in both arms but there was a greater reduction in the intervention arm. Intriguingly, there was no significant difference in  prevalence of tuberculosis infection in children aged 5 at the end of the trial. This trial makes an important cont ..read more
Visit website
October ’19: IGRAs…are they fit for purpose and do resistors really exist?
North London TB Journal Club
by northlondontb
4y ago
North London TB JC and UCL-Tb look forward to welcoming you to October’s JC, where we will discuss the recent publication in Nature, IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure – Lu et al, Nature Medicine 2019 Synopsis: In this paper, Lu and colleagues report detailed investigation of a Ugandan cohort highly exposed to M. tuberculosis, but who repeatedly test negative using conventional latent TB diagnostics. Intriguingly, they find that these individuals demonstrate interferon gamma-independent adaptive responses to M. tb, in the form of both T cell and antibody re ..read more
Visit website
September ’19: Can anyone be successfully treated with a 4-month regimen?
North London TB Journal Club
by northlondontb
4y ago
September Journal Club at the MRC CTU : “A patient-level pooled analysis of treatment shortening regimens for drug-susceptible pulmonary tuberculosis” – Imperial et al, Nature Medicine, November 2018 Three recent trials using 4-month, moxifloxacin containing regimens failed to show non-inferiority in comparison to 6 months of standard HRZE therapy in patients with smear positive, drug sensitive tuberculosis. In this paper Imperial and colleagues re-analysed data from 3,405 participants in these trials to identify populations eligible for 4-month treatment, define phenotypes that are hard to tr ..read more
Visit website
Tb Journal Club is on Summer Break
North London TB Journal Club
by northlondontb
4y ago
North London TB Journal Club is on summer break in August 2019. However, we will be back in September 2019, with a new schedule for the coming year. Details to follow soon. We say goodbye and good luck in the future to Dr Naomi Walker, who has worked hard to organise this years events and welcome Dr Robin Basu Roy, who will join Dr Oshani Dissanayake in organising the journal clubs for the Academic year 2019-20. In the meantime, you may be interested in some of the following: The London Advanced Tb Course Listen to the LSHTM Vaccine Centre podcasts on TB Catch up on World Tb Day, held in Marc ..read more
Visit website

Follow North London TB Journal Club on FeedSpot

Continue with Google
Continue with Apple
OR